Malignant Lung Neoplasm — Trials

Malignant Lung Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

11,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,648
Recruiting: 1,431
Ph III recruiting: 179
Growth YoY: +7.9%
Industry share: 37%
Top sponsor: AstraZeneca
Termination share: 34.8%
Trials / 1,000 deaths: 20.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,489)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03792503	Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen	withdrawn	Phase 4	0	Xinqiao Hospital of ChongqingOTHER	1	Feb 28, 2024	clinicaltrials
NCT03302221	Regional Haemodynamic Changes in Radial Artery Assessment With Continuous Pulsed-wave Doppler Ultrasound	withdrawn	Phase 4	0	China Medical University, ChinaOTHER	1